Home > Inhibitors & Agonists > JAK/STAT Signaling > STAT
Cat. No. Product name CAS No.
DC12010 ML116

A novel selective STAT3 inhibitor with IC50 of 4.2 uM, does not inhibit STAT1, STAT5, or NFkB signaling pathways (IC50>50 uM).

DC11882 HJC0416

A orally bioavailable small-molecule STAT3 inhibitor.

DC12009 CPA-7

A platinum-containing compound that disrupts STAT3 signaling, inhibits cell growth and induces apoptosis in STAT3-activated cancer cells.

DC11420 AS-1517499 Featured

AS1517499 is a potent STAT6 inhibitor with IC50 of 21 nM.

DC8040 STAT3 Inhibitor XVIII, BP-1-102 Featured

BP-1-102 is a potent, orally bioavailable and selective STAT3 inhibitor.

DC10864 C188-9 Featured

C188-9 is a potent inhibitor of STAT3 that binds to STAT3 with high affinity (KD=4.7±0.4 nM). C188-9 is well tolerated in mice, shows good oral bioavailability, and is concentrated in tumors.

DC10111 Debio 0617B

Debio 0617B has been developed as a first-in-class kinase inhibitor with a unique profile targeting phospho-STAT3 (pSTAT3) and/or pSTAT5 in tumors through combined inhibition of JAK, SRC, ABL, and class III/V receptor tyrosine kinases (RTK).

DC8726 FLLL31 Featured

FLLK31 is a potent and selective inhibitor of the STAT3 signaling pathway.

DC7751 FLLL32 Featured

FLLL32, a novel curcumin analogue, is a potent STAT3 inhibitor.

DC10626 HJC0152

HJC0152 is a signal transducer and activator of transcription 3 (STAT3) inhibitor with remarkably improved aqueous solubility.

DC10555 inS3-54A18 Featured

inS3-54A18 is a potent STAT3 inhibitor, with anti-cancer properties.

DC8474 Napabucasin (BBI608) Featured

Napabucasin (BBI608) is an orally-administered small molecule which can block cancer stem cell (CSC) self-renewal and induces cell death in CSCs as well as non-stem cancer cells.

DC9691 Piperlongumine Featured

Piperlongumine induces cell death and increases the level of reactive oxygen species (ROS) in cancer cells with both wild-type and normal p53.

DC7983 SH-4-54 Featured

SH-4-54 is a potent STAT inhibitor with KD of 300 nM and 464 nM for STAT3 and STAT5, respectively.

DC10105 SH5-07 Featured

SH5-07 is a hydroxamic acid based Stat3 inhibitor with an IC50 of 3.9±0.6 μM in in vitro assay.

DC10139 Stat5 Inhibitor(STAT5-IN-1) Featured

Stat5 Inhibitor is a cell permeable nonpetidic nicotinoyl hydrazone which suppresses Stat5 via binding to the SH2 domain.

DC40121 (R)-Lisofylline

(R)-Lisofylline ((R)-Lisophylline) is a (R)-enantiomer of the metabolite of Pentoxifylline with anti-inflammatory properties. (R)-Lisofylline is a lysophosphatidic acid acyltransferase inhibitor with an IC50 of 0.6 μM and interrupts IL-12 signaling-mediated STAT4 activation. (R)-Lisofylline has the potential for type 1 diabetes, autoimmune disorders research.

DC41460 Angoline

Angoline is a potent and selective IL6/STAT3 signaling pathway inhibitor with an IC50 of 11.56 μM. Angoline inhibits STAT3 phosphorylation and its target gene expression, and inhibits cancer cell proliferation.

DC41461 Angoline hydrochloride

Angoline hydrochloride is a potent and selective IL6/STAT3 signaling pathway inhibitor with an IC50 of 11.56 μM. Angoline hydrochloride inhibits STAT3 phosphorylation and its target gene expression, and inhibits cancer cell proliferation.


APTSTAT3-9R, a specific STAT3-binding peptide, inhibits STAT3 activation and downstream signaling by specifically blocking STAT3 phosphorylation. APTSTAT3-9R exerts antiproliferative effects and antitumor activity.

DC44161 AS1810722

AS1810722 is an orally active and potent STAT6 inhibitor with an IC50 of 1.9 nM. AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722 has the potential for allergic diseases such as asthma and atopic diseases.

DC45278 Colivelin Featured

Colivelin is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro. Colivelin exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease. Colivelin has the potential for the treatment of alzheimer's disease and ischemic brain injury

Page 1 / Total 3 FirstPrevNextLastGoto